Carolyn Fairbanks, PhD
Associate Dean for Research, College of Pharmacy
Associate Dean for Research, College of Pharmacy
Professor, Department of Pharmaceutics
Associate Professor, Department of Neuroscience
Professor, Department of Pharmacology
PhD in Pharmacology, University of Minnesota
Bachelor of Biology, Macalester College
The spinal cord carries pain signals to the brain via excitatory neurotransmission and contains most of the same inhibitory neurotransmission systems as the brain. Spinal delivery of analgesics that activate such inhibitory systems offers a very selective method of pain control that can increase the therapeutic index of such analgesics by reducing or eliminating their exposure to brain regions that mediate undesired side effects.
Dr. Carolyn Fairbanks’ research focuses on development of novel compounds with a pharmacokinetic/dynamic profile ideal for spinal delivery for pain relief. One major focus is the continued characterization and clinical translation of a new compound, moxonidine, as well as its corresponding target, the alpha2C adrenergic receptor. The spinal cord contains alpha2C adrenergic receptors on intrinsic spinal neurons which, when activated by agonists such as moxonidine, inhibit action potentials that transmit the pain signal from the periphery to the brain. Dr. Fairbanks’ studies of moxonidine have used methods that incorporate the use of transgenic mice, antisense oligonucleotides and immunocytochemistry.
A second interest of Dr. Fairbanks’ team includes understanding the basic spinal neural mechanisms (glutamate-induced plasticity) governing induction chronic pain as well as opioid-induced tolerance and addiction. Her laboratory currently researches the role of an endogenous amine, agmatine (decarboxylated arginine), in those biological events. Studies of glutamatergic and agmatinergic neurotransmission in the spinal cord apply behavioral, biochemical, immunocytochemical and molecular techniques. Acquiring such information may lead to the development of a novel class of spinally delivered drugs intended for reversing (rather than alleviating) the effects of chronic pain.
Gore, R, Riedl, MS, Kitto, KF, Fairbanks, CA & Vulchanova, L 2019, ‘AAV-Mediated Gene Delivery to the Enteric Nervous System by Intracolonic Injection’ Methods Mol Biol, vol. 1950, pp. 407-415. https://doi.org/10.1007/978-1-4939-9139-6_24
Peterson, CD, Skorput, AGJ, Kitto, KF, Wilcox, GL, Vulchanova, L & Fairbanks, CA 2019, ‘AAV-Mediated Gene Delivery to the Spinal Cord by Intrathecal Injection’ Methods Mol Biol, vol. 1950, pp.199-207. https://doi.org/10.1007/978-1-4939-9139-6_11
Pflepsen, KR, Peterson, CD, Kitto, KF, Vulchanova, L, Wilcox, GL & Fairbanks, CA 2019, ‘Detailed Method for Intrathecal Delivery of Gene Therapeutics by Direct Lumbar Puncture in Mice’ Methods Mol Biol, vol. 1937, pp. 305-312. https://doi.org/10.1007/978-1-4939-9065-8_20
Waataja, JJ, Peterson, CD, Verma, H, Goracke-Postle, CJ, Séguéla, P, Delpire, E, Wilcox, GL & Fairbanks, CA 2019, ‘Agmatine preferentially antagonizes GluN2B-containing N-methyl-d-aspartate receptors in spinal cord’ J Neurophysiol, vol. 121, no. 2, pp. 662-671. https://doi.org/10.1152/jn.00172.2018
Skorput, AGJ, Zhang, X, Waataja, JJ, Peterson, CD, Riedl, MS, Kitto, KF, Truong, H, Huffman, C, Salton, SR, Fairbanks, CA, Honda, CN & Vulchanova, L 2018, ‘Involvement of the VGF-derived peptide TLQP-62 in nerve injury-induced hypersensitivity and spinal neuroplasticity’ Pain, vol. 159, no. 9, pp. 1802-1813. https://doi.org/10.1097/j.pain.0000000000001277
Peterson, CD, Kitto, KF, Akgün, E, Lunzer, MM, Riedl, MS, Vulchanova, L, Wilcox, GL, Portoghese, PS & Fairbanks, CA 2017, ‘Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice’ Pain, vol. 158, no. 12, pp. 2431-2441. https://doi.org/10.1097/j.pain.0000000000001050
Doolen, S, Cook, J, Riedl, M, Kitto, K, Kohsaka, S, Honda, CN, Fairbanks, CA, Taylor, BK & Vulchanova, L 2017, ‘Complement 3a receptor in dorsal horn microglia mediates pronociceptive neuropeptide signaling’ Glia, vol. 65, no. 12, pp. 1976-1989. https://doi.org/10.1002/glia.23208
Laoharawee, K, Podetz-Pedersen, KM, Nguyen, TT, Evenstar, LB, Kitto, KF, Nan, Z, Fairbanks, CA, Low, WC, Kozarsky, KF & McIvor, RS 2017, ‘Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer’ Hum Gene Ther, vol. 28, no. 8, pp. 626-638. https://doi.org/10.1089/hum.2016.184
Chabot-Doré, AJ, Millecamps, M, Naso, L, Devost, D, Trieu, P, Piltonen, M, Diatchenko, L, Fairbanks, CA, Wilcox, GL, Hébert, TE & Stone, LS 2015, ‘Dual allosteric modulation of opioid antinociceptive potency by ?2A-adrenoceptors’ Neuropharmacology, vol. 99, pp. 285-300. https://doi.org/10.1016/j.neuropharm.2015.08.010
Guedon, JM, Wu, S, Zheng, X, Churchill, CC, Glorioso, JC, Liu, CH, Liu, S, Vulchanova, L, Bekker, A, Tao, YX, Kinchington, PR, Goins, WF, Fairbanks, CA & Hao, S 2015, ‘Current gene therapy using viral vectors for chronic pain’ Mol Pain, vol. 11, p. 27. https://doi.org/10.1186/s12990-015-0018-1
NSC/PHM/MVB 8481: Advanced Neuropharmaceutics (Fall semester)